Silexion Therapeutics Corp (SLXN)
| Market Cap | 12.97M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.36M |
| Shares Out | 8.32M |
| EPS (ttm) | -9.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 691,447 |
| Open | 1.480 |
| Previous Close | 1.470 |
| Day's Range | 1.451 - 1.700 |
| 52-Week Range | 1.325 - 13.560 |
| Beta | 0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 29, 2024 |
About SLXN
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre... [Read more]
News
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
The combined company's shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024 The combined company's shares and warrants are ...
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. (“Silexion”), a clin...
MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION
New York, NY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa” or the “Company”) announced today that, in connection with its previously announced extraordinary gen...